Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
Outline of Final Research Achievements |
We previously reported that low-dose IL-2 can induce immune-tolerance with the increase of Treg. However, Treg increase might reduce GVL effect. Therefor, we need to develop the technique to regulate Treg homeostasis during low-dose IL-2 therapy. In this study, our murine study and human subject analysis clearly demonstrated that PD-1 signaling has indispensable role for Treg homeostasis during IL-2. Our results might provide important information for the development of the Treg-based immune therapy for patients after HSCT.
|